Matinas BioPharma
MTNB
28 hedge funds and large institutions have $260K invested in Matinas BioPharma in 2025 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
84% more capital inflows, than outflows
Capital inflows: $217K | Capital outflows: $118K
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
8% more funds holding
Funds holding: 26 → 28 (+2)
0.42% more ownership
Funds ownership: 6.49% → 6.91% (+0.42%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$77.5K |
| 2 |
DRW Securities
Chicago,
Illinois
|
+$54.6K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$24.9K |
| 4 |
XTX Topco
George Town,
Cayman Islands
|
+$19.9K |
| 5 |
Jane Street
New York
|
+$18.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
-$42.7K |
| 2 |
SIG
Sargent Investment Group
Bethesda,
Maryland
|
-$28.2K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$23.7K |
| 4 |
HRT Financial
New York
|
-$20K |
| 5 |
Citigroup
New York
|
-$2.38K |
MTNB Hedge Fund Activity: Q4 2025 in Review
28 of the 8,287 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q4 2025, worth a combined $260K — down 58% from $618K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new MTNB positions and 5 closed out — a net gain of 2 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $77.5K. The largest seller was Northern Trust, exiting entirely with an estimated $42.7K sold.
- 28 institutional investors held Matinas BioPharma (MTNB) as of Q4 2025, up from 26 in Q3 2025.
- Funds reported $260K of Matinas BioPharma stock for Q4 2025, down 58% quarter-over-quarter.
- 7 funds opened new Matinas BioPharma positions in Q4 2025 and 5 closed out, a net change of +2 holders.
- The largest Matinas BioPharma buyer in Q4 2025 was Citadel Advisors, an estimated $77.5K added.
- The largest Matinas BioPharma seller in Q4 2025 was Northern Trust, an estimated $42.7K sold.
Based on aggregated 13F filings for Q4 2025.